Axon Enterprise shares lag Nasdaq as convertible note offering weighs on sentiment
The public-safety technology firm has underperformed the broader index over the past year, with recent volatility triggered by a $1 billion debt raise and concerns over equity dilution.
Axon Enterprise shares have struggled to keep pace with the broader market over the past 12 months, declining 37.6% while the Nasdaq Composite advanced 16.3%. The Scottsdale, Arizona-based firm, which holds a market capitalisation of $60.5 billion, has faced significant headwinds despite its position as a large-cap public-safety technology provider.
The stock recently experienced a sharp pullback, falling 40.9% from its 52-week high of $792.15, which was reached on 23 September 2025. However, signs of a rebound have emerged in the short term, with the shares surging 7.6% over the past three months. This recent performance has outpaced the Nasdaq Composite, which declined 1.5% during the same period.
Despite the short-term recovery, the longer-term picture remains challenging for investors. Axon is down 17.5% year to date, compared with an 11.8% gain for the Nasdaq. Technically, the stock has remained below both its 50-day and 200-day moving averages since early September, reflecting continued downward pressure on the shares.
A key catalyst for recent volatility was the announcement on 15 September of a $1 billion offering of 0% convertible senior notes due in 2031. Axon shares plunged 9.8% on the day of the announcement as investors weighed the potential for equity dilution. Although the notes carry no cash interest, the option to convert into equity has raised concerns among market participants.
The fundraising effort comes at a time when the company’s cash position has tightened significantly. Axon’s cash balance has fallen from approximately $1.7 billion in late 2025 to below $700 million by mid-2026. The company has cited the need to fund growth initiatives and preserve financial flexibility as the primary drivers for the capital raise.
In a comparative analysis, Axon has lagged behind its top rival, L3Harris Technologies. L3Harris stock has decreased 11.8% over the past 52 weeks and 14.6% on a year-to-date basis, a smaller decline than that experienced by Axon.
Despite the recent volatility and underperformance, analysts remain bullish on the company’s longer-term prospects. Among the 15 analysts covering the stock, the consensus rating stands at "Strong Buy," with a mean price target of $715.26. This target implies an upside potential of 52.7% from current market prices.
